This new agreement might signal the beginning of the end for compounded GLP-1s, both due to legal pressure from the FDA and GLP-1 makers as well as the steady drop in list prices for authorized products, which are now finally close to the prices for compounded versions
Let's map out what actually happens
10.1164/rccm.200907-1047OC Am
i,j was weighted by sample size, assumed to be normally distributed, with a mean of 0 and variance of 2 /(N i,j /100)
The FDA label categorizes interactions by mechanism and magnitude
[9] Second, sermorelins reassuring historical tolerability was established with an approved, quality-controlled product in children